The Hong Kong Institute of Directors (“HKIoD”) has today announced the results of the “2020 HKIoD Corporate Governance Scorecard”. A…
Browsing: Business
The Orange wholesale arm, International Carriers, has signed a partnership deal with PLDT for international voice aggregation services to deliver…
SEOUL, KOREA, Apr 24, 2020 – (ACN Newswire) – Suprema, a global leader in security and biometrics, has announced ‘Suprema…
Mr. Shi Bo is a Master of Economics, Chartered Financial Analyst (CFA), Deputy General Manager, Chief Investment Officer (Equity) and…
HONG KONG, Apr 6, 2020 – (ACN Newswire) – Start-up Express, a development programme launched by the Hong Kong Trade…
NEW YORK, NY, Apr 3, 2020 – (ACN Newswire) – Contentos has partnered with the decentralized video delivery protocol Theta Network, which will be…
JS Global Lifestyle Company Limited (“JS Global Lifestyle” or the “Company”, together with its subsidiaries, the “Group”; 1691.HK) announces consolidated…
The globally leading onshore oil rig supplier Honghua Group Limited (Ticker: 196.HK, “Honghua” or “the Company”) today announced unaudited consolidated…
Toll Income up 27.4% to approximately RMB1,255 million with RMB0.12 of Final Dividend Shows a Prominent Sustainable Development Chengdu Expressway…
The Morningstar International Fund Awards are set to recognize the China 2020 winners on March 26. The China Southern Selected…
Total Attributable Contracted Sales to Be Booked Exceeds HK$10 billion; Laying a Solid Foundation for its Profit in the Future…
The four core segments grew steadily. Improvement of profitability led to a substantial increase in net profit attributable to equity…
Both Revenue And Net Profit Harvest, The Profit Attributable To Shareholders Increased By 48.5% Sichuan Languang Justbon Services Group CO.,…
The “True Art of Investments is Boundless”: Confident of Record Performance in 2020 As the markets contemplate the ‘darkest week…
Smartac Group China Holdings Limited (HKEX: 395) (“Smartac” or the “Group”) has announced that the Group has entered into franchise…
Net Profit Up 39.3% to RMB295.1 Million; Income from Factoring and Other Services Surges 29.0% to RMB606.7 Million Sheng Ye…
AUM Increases to HK$157.0 billion, Hitting Historical High China Everbright Limited (“Everbright” or “the Group”, stock code: 165.HK) today announced…
SMEs advised to diversify into northern Vietnam, Greater Bay Area The confidence level of Hong Kong’s exporters has fallen to…
专注于研发治疗免疫疾病，病毒性疾病和多种癌症疗法的免疫药物公司AIM ImmunoTech（纽约证券交易所股票代码：AIM）今天宣布，日本国立传染病研究所（NIID）将 开始测试AIM的药物安普利近（Ampligen），以作为SAV-CoV-2引起的新型冠状病毒感染性疾病——新型冠状病毒肺炎的潜在治疗药物。 实验项目将在NIID和东京大学进行。 测试和研究工作目前正在由NIID流感病毒研究中心主任、东京世界卫生组织（WHO）流感参考和研究合作中心主任Hideki Hasegawa（医学博士、科学博士），和NIID病理学系、东京理工大学生物科学与技术系Ishiohe Takeshi（科学博士）共同主持进行。 “正如我们一直所说的，这种新出现的大规模流行病是由一种病毒引起的，这种病毒的调节RNA序列与原始的SARS冠状病毒(SARS-CoV-1)在发病机制上几乎相同。这意味着先前在SARS-CoV-1动物实验中对安普利近的研究预示着它对新病毒可能会起到类似保护作用。世界卫生组织最近将这种新出现的高致病性病毒更名为SARS-CoV-2。”AIM首席执行官Thomas K. Equels表示。“在美国国立卫生研究院的动物实验中，安普利近对早前的SARS冠状病毒表现出优异的抗病毒活性。在对感染了SARS的小鼠的研究中，安普利近是唯一一种被证明具有显著存活效应的药物：接受安普利近治疗的小鼠存活率达到100%，而未接受治疗的小鼠则无一存活。鉴于SARS-CoV-2与SARS-CoV-1有许多关键的相似之处，在目前尚无针对这种高致病性冠状病毒的有效疗法的情况下，安普利近可能在研发保护性早发疗法中起到关键作用。我们很自豪能与日本备受尊敬的NIID合作，共同抗击这一潜在的流行病。” 安普利近作为一种广谱抗病毒药物具有非常完善的安全性（请参阅：https://aimimmuno.com/events-presentations/ “ 安普利近作为一种抗病毒药物”，安全幻灯片7-15）。 AIM将向股东和市场及时披露最新成果。 参考美国国立卫生研究院（NIH）签订的安普利近治疗SARS的研究： – Day 2009: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787736/ – Barnard 2006: https://journals.sagepub.com/doi/abs/10.1177/095632020601700505…
Share offer of 375,000,000 ordinary shares at between HK$0.335 and HK$0.380 per share expected to raise net proceeds of approximately…